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We present the preliminary toxicity data from the MRC COIN trial, a phase III randomised controlled trial of first-line therapy in
advanced colorectal cancer, with particular reference to the addition of cetuximab to an oxaliplatin–fluoropyrimidine combination. A
total of 804 patients were randomised between March 2005 and July 2006 from 78 centres throughout the United Kingdom. Patients
were allocated to oxaliplatin plus fluoropyrimidine chemotherapy with or without the addition of weekly cetuximab. The choice of
fluoropyrimidine (either 5-fluorouracil (5FU) or capecitabine) was decided by the treating physician and patient before
randomisation. Toxicity data were collected from all patients. Two hundred and three patients received 5FU plus oxaliplatin
(OxMdG, 25%), 333 oxaliplatinþcapecitabine (Xelox, 41%), 102 received OxMdGþcetuximab (OxMdGþC, 13%) and 166
Xeloxþcetuximab (21%). Percent grade 3/4 toxicities included diarrhoea 6, 15, 13 and 25%, nausea/vomiting 3, 7, 7 and 14% for
OxMdG, Xelox, OxMdGþC and XeloxþC, respectively. Sixty-day all-cause mortality was 6, 5, 5 and 7%. Statistically significant
differences were evident for patients receiving Xeloxþcetuximab vs Xelox alone: diarrhoea relative risk (RR) 1.69 (1.17, 2.43,
P¼0.005) and nausea/vomiting RR 2.01 (1.16, 3.47, P¼0.012). The excess toxicity observed in the oxaliplatin-, capecitabine-,
cetuximab-treated patients led the trial management group to conclude that a capecitabine dose adjustment was required to
maintain safety levels when using this regimen.
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Advanced colorectal cancer (ACRC) causes over half a million
deaths worldwide each year (http://www-dep.iarc.fr/). The treat-
ment of ACRC is improving. Average survival has improved from 6
months with best supportive care alone, through 10–12 months
with single-agent 5-fluorouracil (5FU) regimens up to 16–21
months in randomised trials using irinotecan, oxaliplatin and
bevacizumab as well as 5FU.
Cetuximab was licensed for use in epidermal growth factor
receptor (EGFR)-expressing ACRC on the basis of the phase II
BOND trial (Cunningham et al, 2004) in which 218 irinotecan-
refractory patients received cetuximab and irinotecan combination
therapy and 111 received cetuximab monotherapy. Although there
was no chemotherapy are comparator arm in this trial, the data
suggested no greater toxicity with the combination therapy than is
expected in patients receiving single-agent irinotecan, other than a
higher proportion of patients with skin rash, a known side effect of
EGFR inhibitor therapy. In the past year, the first randomised data
on the combination of oxaliplatin and capecitabine in the first-line
ACRC setting have been presented (Cassidy et al, 2008). In
addition, first-line data are also now available from randomised
trials investigating the addition of cetuximab to combination
chemotherapy regimens containing both irinotecan (Van Cutsem
et al, 2007) and oxaliplatin (Bokemeyer et al, 2007).
Antibodies targeting the EGFR have now shown efficacy in third-,
second- and first-line therapies. In the Crystal trial, the addition of
cetuximab to first-line irinotecan, infusional 5FU and folinic acid
resulted in an 8% increase in response rate and a significant
improvement in progression-free survival (P¼0.036) (Van Cutsem
et al, 2007). The EPIC trial explored the use of irinotecan in
combination with cetuximab in the second line, after irinotecan
failure. This trial has recently been published and demonstrated a
response rate with cetuximab and irinotecan of 16.4% (95%
confidence interval (CI), 13.6–19.4), compared with 4.2% (95% CI,
2.8–6.0) with irinotecan alone (P¼0.0001) (Sobrero et al, 2008).
COIN is an open-label multicentre randomised controlled trial
sponsored by the UK Medical Research Council (MRC) and
coordinated by the MRC Clinical Trials Unit (MRC CTU),
comparing two experimental arms with the control arm of
oxaliplatin and fluoropyrimidine chemotherapy in the first-line
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streatment of ACRC. The fluoropyrimidine can be either capecita-
bine or bolus and infusional 5FU (in a modified FOLFOX
regimen), and is chosen on a per-patient or per-institution basis
before randomisation. Two primary questions are being addressed
in the trial. The first question asks whether the addition of
cetuximab to combination chemotherapy will increase overall
survival, whereas the second asks whether intermittent chemo-
therapy treatment is comparable with continuous treatment to
progression or cumulative toxicity.
The use of intermittent chemotherapy is controversial. A previous
MRC trial showed no detriment in overall survival, with an
improvement in toxicity and quality of life for patients receiving
intermittent single-agent 5FU chemotherapy (Maughan et al, 2003).
The Optimox 1 trial showed that discontinuation of oxaliplatin after
six cycles of OxMdG, with continuation of infusional 5FU and
subsequent reintroduction of oxaliplatin, resulted in equivalent
disease control and survival (Tournigand et al,2 0 0 6 ) .T h eO p t i m o x2
study, however, has raised doubts about the overall survival
equivalence for patients given a chemotherapy-free interval. The
original design of Optimox 2 was a phase III trial of 600 patients;
however, accrual was discontinued when bevacizumab became
available. At this stage, only 200 patients had been entered. The
trial reported a non-significant overall median survival difference of
25 months with continuous infusional 5FU, compared with 19
months in the arm with chemotherapy-free intervals (P¼0.056)
(Maindrault-Goebel et al, 2007). Owing to the failure of this trial to
complete accrual as planned, and therefore answer the question
originally posed, it is of utmost importance to obtain reliable phase
III evidence of the relative benefits of continuous chemotherapy vs
intermittent chemotherapy with a chemotherapy-free interval in the
treatment of ACRC. The COIN trial will be the largest randomised
controlled trial of continuous vs intermittent chemotherapy carried
out to date. If successful, the intermittent chemotherapy strategy
would not only benefit patients, who value time off chemotherapy
very highly, but also open a new therapeutic window for the
evaluation and use of novel agents to maintain disease control
during intervals off chemotherapy.
In this paper, we present toxicity reported during the first 12
weeks of treatment for the first 804 patients randomised into the
COIN trial. During the first 12 weeks, there is no difference in the
treatment received by those patients randomised to the control
arm of COIN and those randomised to intermittent therapy.
Therefore, the focus of this paper is the toxicity experience in the
first 12 weeks associated with the addition of cetuximab to two
different oxaliplatin and fluoropyrimidine combination che-
motherapy regimens. The 12-week time point has been chosen as
this is when patients randomised to intermittent therapy stop
treatment. We propose to publish the longer term toxicity data
(relating to the intermittent vs continuous strategies) at a later
date, together with quality of life and primary outcome data. In the
meantime, however, we feel that the initial toxicity experience
contains information of value to clinicians employing combina-
tions of these widely available agents.
PATIENTS AND METHODS
Accrual update
The COIN trial opened to accrual in March 2005 and closed in May
2008 after completing accrual ahead of schedule; 2445 patients
have been randomised from 111 centres in the United Kingdom
and Republic of Ireland.
Eligibility criteria
Patients have histologically confirmed colorectal adenocarcinoma,
with inoperable metastatic or locoregional disease. Eligibility
criteria include disease measurable by RECIST (Therasse et al,
2000) WHO performance status 0–2; no previous chemotherapy
for metastatic disease; neutrophils41.5 10
9 per l, platelet
count4100 10
9 per l, serum bilirubinr1.25  upper limit of
normal (ULN), alkaline phosphatasep5 ULN, calculated GFR or
EDTA clearance X50mlmin
 1; and age 418 years. Exclusion
criteria include patients receiving combination chemotherapy
before the resection of operable liver metastases (patients of
uncertain operability are eligible), brain metastases, prior adjuvant
chemotherapy with oxaliplatin and uncontrolled medical co-
morbidity likely to compromise treatment.
Randomisation and treatment
Patients were randomised centrally by the MRC CTU to one of the
three trial arms on a 1:1:1 basis using a stratified, minimisation
procedure. Treatment is started as soon as possible after
randomisation and within 4 weeks of the baseline radiological
disease assessment using CT scan. The trial arms are as follows:
Arm A:
Continuous chemotherapy (control arm) The chemotherapy regi-
men is a combination of oxaliplatin and a fluoropyrimidine.
The regimens are:
OxMdG: a combination of l-folinic acid (175mg i.v. over 2h) OR
d,l-folinic acid (350mg i.v. over 2h), concurrent administration
of oxaliplatin (85mgm
 2 i.v. over 2h) plus bolus 5FU
(400mgm
 2) followed by a 46-h i.v. infusion of 5FU
2400mgm
 2 repeated every 2 weeks as used in the FOCUS trial
(Seymour et al, 2007) or
Xelox: a combination of oxaliplatin 130mgm
 2 i.v. over 2h on
day 1 plus capecitabine 1000mgm
 2 b.d., p.o. on days 1–14
repeated thrice weekly.
Patients continue chemotherapy until RECIST-defined progres-
sive disease is identified, or the development of cumulative toxicity
or because of patient choice to stop chemotherapy. Patients should
have no more than a 3-week interval off treatment for any reason.
Arm B:
Continuous chemotherapy plus cetuximab Cetuximab is adminis-
tered once weekly in combination with the chemotherapy schedules
as above. On day 1 of the first cycle of chemotherapy, an initial
loading dose of 400mgm
 2 cetuximab is given by 2-h i.v. infusion
and then continued weekly at a dose of 250mgm
 2 over 60min. The
following pre-medication is administered at each administration: i.v.
chlorphenamine 10mg, paracetamol (acetaminophen) 1g p.o. and
ranitidine 150mg p.o. Dexamethasone 8mg i.v. is given on days
when oxaliplatin is also given. Patients continue chemotherapy plus
cetuximab as in arm A above. Cetuximab may be continued if
chemotherapy is stopped because of toxicity or patient choice, but
should be discontinued on evidence of disease progression or
unacceptable cetuximab toxicity.
Arm C:
Intermittent chemotherapy These patients are treated initially for
12 weeks as in arm A. Patients who have radiologically confirmed
progressive disease at this point come off study, as in arms A and B.
Patients with stable or responding disease stop chemotherapy and
are monitored clinically, at least six weekly, and with CT scans at 12-
weekly intervals. On evidence of radiological disease progression or
on clinical evidence of deterioration, the same chemotherapy is
restarted, for a further 12-week course. At that point, treatment is
again interrupted. Patients with chemosensitive disease may have an
unlimited number of 12-week treatments alternating with treatment
breaks. When the patient demonstrates resistance to this treatment
as evidenced by progressive disease during a period on chemo-
therapy, they move on to second-line therapy or supportive care.
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sProtocol dose modifications
Detailed dose reduction and delay protocols are given in the
protocol. In general, unresolved grade X2 toxicity required a
1-week delay, whereas grade X3 toxicity or two delays for grade 2
toxicity required a 20% dose reduction.
Assessments
Investigator assessments of toxicity are made at six-weekly
intervals while on protocol treatment and scored using NCI CTC
criteria (version 3.0). Safety is assessed continuously throughout
the trial by monitoring of adverse events by the treating physician.
Reported serious adverse events are reviewed by an experienced
practicing oncologist. All deaths, together with the treating
physician’s assessment of causality, are also reported. A further
assessment of cause of death is also undertaken centrally by an
experienced practicing oncologist (TSM, RA or AyM).
Statistical methods
As arms A and C are identical during the first 12 weeks of protocol
treatment, they are combined for the purpose of this analysis. All
comparisons were tested for significance using Fisher’s exact tests.
All reported P-values are two-sided, and P-values less than 0.05
were considered to indicate statistical significance.
Role of the funding source
The trial is funded by Cancer Research UK, the MRC and
supported by an educational grant from Merck Serono. Patient
informed consent and data collection were supported by staff from
the National Cancer Research Networks across the United King-
dom.
Trial governance
COIN is an investigator-initiated trial sponsored by the MRC in the
United Kingdom. Certain sponsor responsibilities are delegated to
the Irish Clinical Oncology Research Group for investigator sites in
the Republic of Ireland. Multicentre and Institutional Research
Ethics Committee and appropriate regulatory approval have been
obtained, and all patients provide written informed consent. Trial
management is by the MRC Clinical Trials Unit following the
principles of ICH GCP and overseen by an Independent Trial
Steering Committee. An Independent Data Monitoring Committee
meets at regular intervals (approximately six monthly) for trial
oversight, including review of safety data and interim outcome
analyses at pre-specified intervals.
RESULTS
Characteristics of patients
From March 2005 to July 2006, 804 patients were randomised at 78
centres in the United Kingdom. Baseline characteristics (Table 1)
were well balanced across the three arms. Thirty-eight percent
received OxMdG and 62% of patients received Xelox. Patients on
average have a high burden of disease at baseline, with
approximately 40% having an unresected or unresectable primary
tumour and each patient having on average 2.3 metastatic sites.
Treatment received
Two hundred and three patients received 5FU plus oxaliplatin
(OxMdG, 25%), 102 received OxMdGþcetuximab (OxMdGþC,
13%), 333 oxaliplatinþcapecitabine (Xelox, 41%) and 166
Xeloxþcetuximab (21%).
At least one dose reduction in a COIN trial drug was instituted
for toxicity in 28, 44, 22 and 49% of patients in the regimens,
respectively. This doubling of dose reductions when chemotherapy
was given with cetuximab was highly statistically significant
(Po0.001). These broke down as indicated in Table 2 (online).
Median dose intensities are as indicated in Table 3 (online). It is of
particular note that in patients on XeloxþC, the oxaliplatin dose
was reduced in 33% of patients compared with 15% on Xelox alone
(Po0.001).
Toxicity
Toxicity data during the first 12 weeks of treatment are available
for 97% of patients. Table 4 (online) indicates all grades of toxicity
reported, whereas Table 5 shows grade 3 or 4 toxicities observed
Table 1 Base-line patient and tumour characteristics
Treatment arm A B C
Total patients 269 (33%) 268 (33%) 267 (33%)
Chemotherapy selection
Ox+Cap 167 (62%) 166 (62%) 166 (62%)
OxMdG 102 (38%) 102 (38%) 101 (38%)
Sex
Male 173 (64%) 167 (62%) 174 (65%)
Female 96 (36%) 101 (38%) 93 (35%)
Age (years)
o45 12 (4%) 18 (7%) 14 (5%)
45–54 46 (17%) 34 (13%) 48 (18%)
55–64 88 (33%) 100 (37%) 91 (34%)
65–74 99 (37%) 95 (35%) 94 (35%)
75+ 24 (9%) 21 (8%) 20 (7%)
Median age (IQR) 63 (56, 69) 63 (58, 69) 63 (55, 70)
WHO PS
0 120 (45%) 124 (46%) 126 (47%)
1 128 (48%) 127 (47%) 126 (47%)
2 21 (8%) 17 (6%) 15 (6%)
Current status of primary tumour
Resected 152 (57%) 144 (54%) 140 (52%)
Unresected/unresectable 103 (38%) 100 (37%) 108 (40%)
Local recurrence 14 (5%) 24 (9%) 19 (7%)
Metastases
No 2 (1%) 2 (1%) 1 (o1%)
Yes 267 (99%) 266 (99%) 266 (499%)
Type of metastases
Liver only 55 (20%) 69 (26%) 67 (25%)
Liver 197 (73%) 195 (73%) 194 (73%)
Nodes 127 (47%) 109 (41%) 119 (45%)
Lung 107 (40%) 103 (38%) 99 (37%)
Peritoneum 40 (15%) 40 (15%) 40 (15%)
Other 38 (14%) 45 (17%) 36 (13%)
Mean no. of metastatic sites
at baseline
2.32 2.3 2.3
Site of primary tumour
Colon 147 (55%) 142 (53%) 136 (51%)
Rectum 82 (30%) 88 (33%) 83 (31%)
Rectosigmoid junction 34 (13%) 37 (14%) 48 (18%)
Other 2 (1%) 1 (o1%) 0 (0%)
Missing data 4 (1%) 0 (0%) 0 (0%)
Prior treatment for patient with metastatic disease
Radiotherapy 9 (3%) 6 (2%) 2 (1%)
Surgery 54 (20%) 49 (18%) 53 (20%)
PS¼performance status.
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randomised to COIN.
The addition of cetuximab to oxaliplatin- and fluoropyrimidine-
based chemotherapy results in an absolute increase in any grade 3/
4 toxicity of approximately 25% (35–63% with OxMdG, 35–57%
with Xelox, Po0.001). Grade 3/4 neutropaenia is significantly
increased in patients receiving infusional 5FU (17% without and
26% with cetuximab) compared with those taking oral capecita-
bine (2% without and 1% with cetuximab, Po0.001), and this
translates into neutropaenic sepsis in 4, 5, 1 and 0%, respectively.
Gastrointestinal toxicities, namely nausea, vomiting and diar-
rhoea, are all significantly increased in patients receiving Xelox
Table 2 Chemotherapy dose reductions over the first 12 weeks of treatment broken down by regimen and therapeutic agent, on line only
Arms A+C (no cetuximab) Arm B (cetuximab)
OxMdG XELOX OxMdG XELOX Total
Total N 203 333 102 166 804
Trial drug
5FU 48 31 79
% of patients with 5FU dose reduction (24%) (30%) (26%
a)
Capecitabine 65 60 125
% of patients with capecitabine dose reduction (20%) (36%) (25%
a)
Oxaliplatin 28 50 16 54 148
% of patients with oxaliplatin dose reduction (14%) (15%) (16%) (33%) (18%)
Cetuximab 24 33 57
% of patients with cetuximab dose reduction (24%) (20%) (21%
a)
Any trial drug 57 73 45 81 256
% of patients with any trial drug dose reduction (28%) (22%) (44%) (49%) (32%)
5FU¼5-fluorouracil. On line only.
aDenominator is valid subjects only.
Table 3 Dose intensities (first 12 weeks; medians and IQRs)
Arms A+C (no cetuximab) Arm B (cetuximab)
OxMdG XELOX OxMdG XELOX Total
Total 203 333 102 166 804
Complete data on first round of treatment (0–12 weeks) 158 247 76 119 600
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
5FU infusion 91 (81, 99) 85 (78, 94) 88 (80, 97)
5FU bolus 91 (75, 99) 83 (68, 93) 88 (71, 97)
Capecitabine 96 (86, 100) 88 (80, 100) 93 (84, 100)
Oxaliplatin 89 (82, 98) 97 (89, 100) 86 (78, 94) 92 (80, 99) 93 (83, 99)
Cetuximab, day 1 85 (78, 94) 96 (87, 100) 92 (81, 99)
Cetuximab, day 8 83 (75, 92) 93 (78, 100) 89 (77, 99)
Cetuximab, day 15 91 (75, 100) 91 (75, 100)
5FU¼5-fluorouracil.
Table 4 Dose intensities (first 12 weeks; percentage of patients with o80%) on line only
Arms A+C (no cetuximab) Arm B (cetuximab)
OxMdG XELOX OxMdG XELOX Total
Total 203 333 102 166 804
Complete data on first round of treatment (0–12 weeks) 158 247 76 119 600
N (%) N (%) N (%) N (%) N (%)
5FU infusion 3 (2) 5 (7) 8 (3)
5FU bolus 24 (15) 16 (21) 40 (17)
Capecitabine 11 (4) 17 (14) 28 (8)
Oxaliplatin 5 (3) 4 (2) 6 (8) 14 (12) 29 (5)
Cetuximab, day 1 1 (1) 12 (10) 13 (7)
Cetuximab, day 8 7 (9) 23 (19) 30 (15)
Cetuximab, day 15 29 (24) 29 (24)
5FU¼5-fluorouracil.
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toxicities are further increased by the addition of cetuximab, with
an incidence of grade 3/4 diarrhoea of 25% in patients receiving
the Xelox plus cetuximab combination. Statistically significant
differences were evident for patients receiving Xelox in combina-
tion with cetuximab-based therapy vs Xelox alone for grade 3/4:
relative risk (RR) of diarrhoea 1.69 (1.17, 2.43, P¼0.005), nausea
or vomiting RR 2.01 (1.16, 3.47, P¼0.012) and lethargy RR 2.08
(1.27, 3.41, P¼0.003).
As expected, patients receiving cetuximab have a significantly
increased incidence of the skin rash associated with EGFR
inhibitors such as cetuximab. This increase is similar irrespective
of the chemotherapy regimen (84% in patients receiving
Xeloxþcetuximab and 85% in patients receiving OxMdG plus
cetuximab). Hand–foot syndrome was significantly more common
with capecitabine, with 40% experiencing any grade but only 2–
4% experiencing grade 3 hand–foot syndrome. There was a trend
to an increased incidence of hand–foot syndrome in patients
treated with cetuximab.
In earlier studies, hypersensitivity reactions have been reported
in 1.8% of patients receiving oxaliplatin chemotherapy, increasing
to 4.1% when cetuximab is added to this chemotherapy regimen
(Bokemeyer et al, 2007). In this cohort, there was no such increase
in oxaliplatin hypersensitivity with the addition of cetuximab,
although numbers are small.
Lethargy is reported in 8% of patients receiving Xelox and 7% of
patients receiving OxMdG chemotherapy. The addition of
cetuximab results in an increase in lethargy, with 17% of patients
Table 5 All grades of toxicity reported in the first 12 weeks of treatment
Arms A+C (no cetuximab) Arm B (cetuximab) Significance*
OxMdG XELOX OxMdG XELOX ±Cap. ±Cet.
N 203 333 102 166
N (%) N (%) N (%) N (%)
Any grade 1+ 194 (96) 316 (95) 100 (98) 161 (97)
Neutropaenia 91 (45) 42 (13) 46 (45) 9 (5) Po0.001
Nausea or vomiting 113 (56) 215 (65) 56 (55) 95 (57)
Diarrhoea 115 (57) 207 (62) 75 (74) 117 (70) Po0.05
Skin rash 23 (11) 44 (13) 87 (85) 139 (84) Po0.001
Hypersensitivity
Any 2 (o1) 6 (2) 0 (0) 4 (2)
Oxaliplatin 1 (1) 4 (1) 0 (0) 1 (o1)
Cetuximab — 0 (0) 2 (1)
Not specified 1 (1) 2 (1) 0 (0) 1 (1)
Lethargy 157 (77) 266 (80) 91 (89) 144 (87) Po0.05
Hand–foot syndrome 33 (16) 89 (27) 42 (41) 70 (42) Po0.001
Peripheral neuropathy 155 (76) 230 (71) 76 (75) 117 (70)
Hypomagnesaemia 6 (3) 7 (2) 9 (9) 7 (4) Po0.05 Po0.05
*Fisher’s exact test. ‘Cap.’¼presence vs absence of capecitabine; that is, XELOX vs OxMdG. ‘Cet.’¼presence vs absence of cetuximab; that is, arm B vs arms A and C.
Table 6 Grade 3 and 4 toxicities reported over first 12 weeks of treatment
Arms A+C (no cetuximab) Arm B (cetuximab) Significance*
OxMdG XELOX OxMdG XELOX ±Cap. ±Cet.
N 203 333 102 166
N (%) N (%) N (%) N (%)
Any grade 3 or 4 72 (35) 118 (36) 64 (63) 95 (58) Po0.001
Neutropaenia 35 (17) 5 (2) 27 (26) 1 (1) Po0.001
Neutropaenic sepsis/febrile neutropaenia 9 (4) 3 (1) 5 (5) 0 (0) Po0.001
Nausea or vomiting 6 (3) 23 (7) 7 (7) 23 (14) Po0.05 Po0.05
Diarrhoea 13 (6) 50 (15) 13 (13) 42 (25) Po0.001 Po0.05
Skin rash 0 (0) 2 (1) 12 (12) 16 (10) Po0.001
Hypersensitivity
Any 0 (0) 1 (o1) 0 (0) 2 (1)
Oxaliplatin 0 (0) 1 (o1) 0 (0) 0 (0)
Cetuximab — 0 (0) 1 (1)
Not specified 0 (0) 0 (0) 0 (0) 1 (1)
Lethargy 15 (7) 27 (8) 21 (21) 28 (17) Po0.001
Hand—foot syndrome 1 (o1) 7 (2) 4 (4) 7 (4)
Peripheral neuropathy 4 (2) 14 (4) 0 (0) 10 (6) Po0.05
Hypomagnesaemia 0 (0) 1 (o1) 0 (0) 0 (0)
*Fisher’s exact test. ‘Cap.’¼presence vs absence of capecitabine; that is, XELOX vs OxMdG. ‘Cet.’¼presence vs absence of cetuximab; that is, arm B vs arms A and C.
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OxMdG plus cetuximab experiencing grade 3/4 lethargy within the
first 12 weeks of their treatment in the COIN trial.
Peripheral neuropathy is rare in this report, as the time for the
report is ‘toxicities within the first 12 weeks of therapy’ and
oxaliplatin neuropathy emerges slightly later than 12 weeks in
most patients in whom it occurs. Longer term data will be available
when the overall trial outcomes are reported. Similarly in this
cohort, hypomagnesaemia is under-reported here because the
protocol was modified in October 2005 to make magnesium
concentration monitoring and reporting mandatory, by which time
most of these patients had commenced treatment.
Deaths within 60 days of randomisation
Tables 6 and 7 shows the numbers and percentages of deaths
within 60 days of randomisation, both all-cause and those
attributed to trial treatment. All-cause 60-day mortality is similar
irrespective of the chemotherapy regimen or the addition of
cetuximab. On review of causation by an experienced practicing
oncologist on behalf of the MRC as a sponsor of the trial,
treatment-related deaths were not statistically significantly differ-
ent between treatment regimens.
DISCUSSION
The COIN trial was designed and completed recruitment during a
period when no strong predictor of response to EGFR-inhibiting
therapies was known or available. K-ras mutation on tumour
samples has since been identified as predictive of minimal
likelihood of benefit from the addition of cetuximab in various
colorectal clinical settings. However, there is as yet no evidence
that somatic k-ras status is associated with differences in toxicity
of EGFR antibodies or small molecule inhibitors. The initial COIN
trial data reported herein encompass the whole eligible population
regardless of k-ras mutation status. When the outcome data are
mature and a full report on (early and late) toxicities accompanies
the analysis, data on k-ras status for almost all of these patients will
be available. It is possible that there may be differences in toxicity
that relate to tumour k-ras mutational status, but that is not the
expectation. The COIN data thus far reflect a typical usage of
cetuximab to date in first-line combinations in patients without
molecular selection.
A number of interesting toxicity issues are addressed by this
study, relating to confirmatory evidence of the differences between
oxaliplatin regimens with either capecitabine or 5FU and to the
novel issues of adding cetuximab to either of these regimens.
The findings of the COIN trial are consistent with other
international trials including the Roche-sponsored Xelox-1/
NO16966 phase III trial in first-line treatment of colorectal cancer,
which reported comparative toxicity for oxaliplatin plus 5FU
compared with oxaliplatin plus capecitabine. The COIN trial also
shows a significantly higher incidence of neutropaenia (with a
4.8% incidence of febrile neutropaenia), and half the incidence of
diarrhoea with the infusional 5FU regimen compared with
capecitabine. Treatment-related mortality in the NO16966 study
was 2.1% with Xelox compared with 1.7% with FOLFOX (Cassidy
et al, 2008) (see Table 8 for comparisons).
The addition of cetuximab to oxaliplatin-based regimens has not
been previously reported in a phase III trial, but data from the
large OPUS phase II study show no significant uplift in toxicity
when combining cetuximab with FOLFOX-4 (a regimen with a
lower infused 5FU dose compared with that used in the COIN trial)
(Bokemeyer et al, 2007).
The addition of cetuximab to 5FU plus irinotecan (FOLFIRI)
was evaluated in the Crystal trial. A minor increase in grade 3 and
4 diarrhoea (from 10 to 15%) was seen with the addition of
cetuximab (Van Cutsem et al, 2007).
Table 8 shows the comparative toxicities from the COIN, Roche
N966, Crystal and OPUS trials. The only studies that have
previously reported the addition of capecitabine-containing
combinations with cetuximab are the SAKK group, the AIO CRC
study group phase II trials and the single-institution study from
Table 7 All-cause 60-day mortality
Arms A+C (no cetuximab) Arm B (cetuximab)
OxMdG XELOX OxMdG XELOX
No. of patients randomised 203 333 102 166
N (%) N (%) N (%) N (%)
60-day all-cause mortality 12 (6%) 18 (5%) 5 (5%) 12 (7%)
Treatment-related death within 60 days 2 (1%) 2 (1%) 1 (1%) 3 (2%)
Table 8 A comparison of toxicities among a variety of chemotherapy regimens within four clinical trials in which cetuximab was used
XELOX
a OxMdG
a FOLFOX
b XELOX
b FOLFIRI
c FOLFOX-4
d
Cetuximab+
XELOX
a
Cetuximab+
OxMdG
a
Cetuximab+
FOLFIRI
c
Cetuximab+
FOLFOX-4
d
N 333 203 649 655 602 168 166 102 600 170
Any grade 3 or 4
toxicity
35 35 78.3 71.5 59.5 NS 57 63 78.0 NS
Neutropaenia 2 17 43.8 7.0 23.3 31.5 1 26 26.7 27.6
Nausea or vomiting 7 3 NS NS 5.0 NS 14 7 4.5 NS
Diarrhoea 15 6 11.2 20.2 10.5 6.0 25 13 15.2 7.1
Skin rash 1 0 NS NS 0.2 0 10 12 18.7 14.1
Hypersensitivity NS NS 0 1.8 2.3 4.1
2.0
Lethargy 8 7 NS NS 4.5 3.0 17 21 5.0 3.5
aCOIN TRIAL.
bRoche N966.
cCrystal trial.
dOPUS trial.
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et al, 2007). The SAKK group performed a randomised phase II
trial of 74 patients in whom all received Xelox (as used in COIN)
on a three-weekly basis and half of the patients received cetuximab
weekly; the toxicity data have recently been published and
demonstrate a non-significant increase in grade 3/4 diarrhoea
from 16 to 22%, with the addition of cetuximab (Borner et al,
2008). The AIO group trial randomised patients to XELIRI or
Xelox both with the addition of cetuximab. In the 41 patients
receiving Xelox plus capecitabine (in a similar dose and schedule
to COIN), grade 3/4 toxicity was seen in 19.5%. The single-centre
Heraklion trial recruited 40 patients and used the two-weekly
capecitabine plus oxaliplatin (CAPOX) regimen in combination
with cetuximab (weekly) with only 7 days of capecitabine. The rate
of grade 3/4 diarrhoea in this trial was 7.5%.
The key finding of this report is the synergistic effect on
diarrhoeal toxicity of the oxaliplatin, capecitabine and cetuximab
combination. This finding had been observed in an earlier IDMC
report and the TMG had, on the instruction of the IDMC,
improved the patient information cards and fed back the data to
investigators so that they include this information in their
discussions with patients regarding selection of capecitabine- or
5FU-based treatment. Despite this, the rate of diarrhoea was
gradually increasing: for those patients receiving oxaliplatin,
capecitabine and cetuximab, a grade 3/4 diarrhoea rate of 23%
was reported in the ASCO abstract (Maughan, 2007) submitted in
December 2006 and this had reached 30% (on the data set from the
March IDMC, released to the TMG as of July 2007). Thus, there was
no sign of an improvement with greater experience of the regime
by investigators despite information to investigators and improved
patient information.
This increased toxicity is reflected in the increased incidence of
dose reduction in those patients receiving cetuximab. Overall,
patients receiving cetuximab had a dose reduction of any agent
twice as often as those without cetuximab. In particular, those
treated with Xeloxþcetuximab had a 33% incidence of oxaliplatin
dose reductions compared with 15% on Xelox alone. It is possible
that such dose reductions may contribute to the impaired
outcomes seen in the OPUS trial in the ras mutant sub-group
treated with FOLFOX plus cetuximab, and this will be analysed
further in the outcomes of the COIN trial.
The trial management group reviewed the data in greater detail
and discussed the possible options. The options included first
making no protocol change, but urging further diligence in
information giving and dose reduction in face of toxicity; dose
reduction in the face of grade 2 toxicity rather than grade 3; or
alternatively, an immediate dose reduction of capecitabine from
1000 to 850mgm
 2 b.d. from cycle 1, which was in line with the
TREE 2 doses and the Expert C protocol.
The advantages of this second option were that this would be the
safest and swiftest course of action to reduce the toxicity for
patients on arm B who choose to use capecitabine as the
fluoropyrimidine. In addition, the data from the revised dose
would provide evidence for a more manageable combination
schedule for the future, which would be consistent with other
international data of capecitabine plus oxaliplatin when used in
combination with a biological agent. Finally, this would provide
for a more equitoxic comparison between arm A (full-dose Xelox)
and arm B (dose-reduced Xeloxþcetuximab).
The disadvantages were considered to be that we would be using
a different regimen for the comparator in arm A (full-dose Xelox)
vs arm B (dose-reduced XeloxþC). This reduced dose intensity for
all subsequent patients on Xeloxþcetuximab might impact on the
efficacy of this combination. This could in turn cause difficulties in
reporting the trial in view of the mid-trial dose reduction for a
subset of patients in arm B. The arm B comparisons of toxicity and
effectiveness would need to be reported as the total intention-to-
treat population (1614 patients) and as three subsets: (1) those
treated on OxMdG: OxMdG vs OxMdGþcetuximab (c 613 patients
on current 38% usage of OxMdG); (2) those on full-dose Xelox
until dose reduction imposed (696 patients); (3) those on modified
Xelox comparing full-dose Xelox vs mXELOXþcetuximab (295
patients). On this basis, the TMG considered that the dose
reduction at this point in the trial would have a modest effect on
the efficacy data, but was required for patient safety.
The option appraisal paper and the toxicity and advised dose
reduction data were reviewed by the IDMC and independent TSC
and the decision to apply the dose reduction was approved and
immediately implemented from July 2007.
CONCLUSION
This data set is consistent with previous data reporting the toxicity
of the addition of cetuximab to combination chemotherapy. There
is an increased incidence of grade 3 and 4 toxicities overall. The
specific toxicities affect the skin, gastrointestinal tract and
lethargy. Infusion-related reactions are relatively rare and can be
largely prevented with combination pre-medication regimens. The
combination of oxaliplatin (130mgm
 2, i.v., q21d), capecitabine
(2000mgm
 2 for 14 out of 21 days) and cetuximab was associated
with an unacceptable rate of grade 3, 4 diarrhoea, and a dose
reduction of capecitabine from 2000 to 1700mgm
 2day
 1 has
been introduced into the trial protocol and is advised for off
protocol use of this triple combination.
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